(0.25%) 5 144.50 points
(0.21%) 38 521 points
(0.34%) 17 907 points
(-0.55%) $83.39
(1.98%) $1.961
(0.05%) $2 348.30
(0.33%) $27.63
(0.87%) $930.10
(-0.21%) $0.933
(-0.31%) $10.99
(-0.35%) $0.798
(1.14%) $92.92
@ $11.85
发出时间: 15 Feb 2024 @ 02:14
回报率: -20.84%
上一信号: Feb 14 - 01:38
上一信号:
回报率: 1.28 %
Live Chart Being Loaded With Signals
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK...
Stats | |
---|---|
今日成交量 | 42 667.00 |
平均成交量 | 143 247 |
市值 | 237.27M |
EPS | $0 ( 2024-03-12 ) |
下一个收益日期 | ( $-1.160 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.37 |
ATR14 | $0.0330 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Calkins Daniel | Sell | 6 | Common Stock |
2024-03-25 | Calkins Daniel | Sell | 25 | Common Stock |
2024-03-20 | Calkins Daniel | Sell | 55 | Common Stock |
2024-03-18 | Gagnon Robert E. | Sell | 283 | Common Stock |
2024-03-19 | Gagnon Robert E. | Sell | 130 | Common Stock |
INSIDER POWER |
---|
50.18 |
Last 99 transactions |
Buy: 1 037 036 | Sell: 241 539 |
音量 相关性
Verastem Inc 相关性
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Verastem Inc 相关性 - 货币/商品
Verastem Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-62 000.00 (0.00 %) |
EPS: | $-3.96 |
FY | 2023 |
营收: | $0 |
毛利润: | $-62 000.00 (0.00 %) |
EPS: | $-3.96 |
FY | 2022 |
营收: | $2.60M |
毛利润: | $2.48M (95.45 %) |
EPS: | $-4.58 |
FY | 2021 |
营收: | $2.05M |
毛利润: | $2.05M (100.00 %) |
EPS: | $-0.464 |
Financial Reports:
No articles found.
Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。